Ventyx Biosciences, Inc.
Ventyx Biosciences, Inc. (VTYX) Stock Overview
Explore Ventyx Biosciences, Inc.’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
202.1M
P/E Ratio
-1.63
EPS (TTM)
$-1.74
ROE
-0.47%
VTYX Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Ventyx Biosciences, Inc. (VTYX) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 68.43, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $0.48.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -1.63 and a market capitalization of 202.1M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.
Technical Indicators
Analyst Recommendations
Price Targets
Company Profile
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, Crohn's disease, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that is in phase II clinical trials for the treatment of ulcerative colitis; and VTX2735, a peripheral-targeted NOD-like receptor protein 3 (NLRP3) inflammasome inhibitor for the treatment of systemic inflammatory diseases, such as cardiovascular, hepatic, renal, and rheumatologic diseases which is in phase I clinical trials. In addition, the company develops CNS-penetrant NLRP3 inhibitors for the treatment of Alzheimer disease, Parkinson disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ventyx Biosciences, Inc. was incorporated in 2018 and is based in Encinitas, California.
Raju S. Mohan
81
662 Encinitas Boulevard, San Diego, CA
2021